In Brief: Forest Labs' Alzheimer's candidates
Executive Summary
Forest Labs' Alzheimer's candidates: Company has a selective muscarinic agonist, AF 102B, in clinicals for Alzheimer's in addition to Synapton (physostigmine salicylate), the firm's acetylcholinesterase inhibitor that showed statistical significance in the primary endpoints of ADAS-Cog and CIBIC-Plus measurements in Phase III trials. The Aug. 19 issue of "The Pink Sheet" (T&G-10) incorrectly described Synapton's action...